Lunsumio and Management of Extravasation

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This article responds to your request for information on Lunsumio® (mosunetuzumab) and the management of extravasation.

Download article Download

Last updated May 16, 2024


  • Lunsumio is a monoclonal antibody.
    • Monoclonal antibodies are classified as non vesicants or as irritants. Extravasation of Lunsumio is not expected to result in outcomes typical for vesicants.
      • There is no specific treatment recommendation following extravasation of Lunsumio.
        • In cases of extravasation, the Lunsumio infusion should be stopped and symptoms of extravasation should be treated as per your institution's protocol for management of extravasation.

          Vesicants, irritants, and non-vesicants

          Chemotherapy drugs may be classified based on their potential to cause tissue damage if extravasation occurs: [1]

          • Vesicants — These drugs may cause pain, inflammation, blistering, tissue death, and necrosis of local skin and underlying structures.
            • Irritants — These drugs may cause pain, inflammation, or irritation but rarely tissue breakdown.
              • Non-vesicants — These drugs are inert or neutral compounds that may cause pain but not inflammation or damage.

                Any chemotherapy drugs have the potential to cause significant symptoms and tissue damage if the volume or concentration of the drug that extravasated is high.[1]

                Potential for Lunsumio to cause tissue damage after extravasation

                Lunsumio is a monoclonal antibody.[2] Monoclonal antibodies are either classified as non vesicants [1,3] or as irritants due to the possibility of local allergic reactions rather than direct cellular toxicity.[4] Extravasation of Lunsumio is not expected to result in outcomes typical for vesicants. 

                Recommendations for the management of extravasation of Lunsumio

                There is no specific treatment recommendation following extravasation of Lunsumio.[5] Please refer to your institution's protocol for management of extravasation.

                The study protocol for a Lunsumio pivotal clinical trial did not include guidance for management of extravasation.[6]

                Clinical guidelines

                Resources for the management of extravasation with chemotherapeutic agents have been published.[1,3,7] Examples include but are not limited to clinical practice guidelines published by the European Society for Medical Oncology (ESMO) [1] and the National Health Service (NHS).[7]

                The ESMO guidelines recommend that in cases of extravasation, the infusion should be stopped and symptoms of extravasation should be treated.[1] Please refer to the full guidelines for further information.

                Extravasation experience from case reports

                Currently there are no case reports published for extravasation of Lunsumio.


                1. Pérez FJA, García FL, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012;23 Suppl 7:vii167-73.
                  1. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23:1055-1065.
                    1. Kreidieh FY, Moukadem HA, El SNS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 2016;7:87-97.
                      1. Pluschnig U, Haslik W, Bartsch R, et al. Extravasation emergencies: state-of-the-art management and progress in clinical research. Memo 2016;9:226-230.
                        1. Roche Internal Regulatory Document (Accessed on 31 July 2023).
                          1. Protocol for Safety and Efficacy of Mosunetuzumab, A Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-arm, Multicentre, Phase 2 Study. Available at Accessed on July 30, 2023.
                            1. Network Guidelines for the Management of Extravasation of a Systemic Anti-Cancer Therapy Including Cytotoxic Agents. Available at Accessed on May 16, 2024.

                              Welcome to Medically

                              The Roche Science Hub

                              This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

                              Not a healthcare professional? Browse:

                              This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

                              You are Leaving Medically

                              By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.